Longitudinal Study of Phenotypic and Developmental Severity in Patients With Dravet Syndrome With SCN1A Gene Mutation

Overview

Dravet syndrome with SCN1A gene mutation is a developmental and epileptic encephalopathy characterized by treatment-resistant epilepsy and global developmental delay. Despite the considerable attention recently Dravet syndrome (DS) in drug development, studies characterising the progression of the neurodevelopmental phenotype over time remain limited. In particular, many previous studies of natural history studies have been of short duration or have focused only on a subgroup of the paediatric population. This prospective natural history study is being conducted to define more precisely the neurodevelopmental trajectory of SCN1A-positive Dravet syndrome in patients aged aged 6 months to 21 years with SCN1A mutations. The study will examine these characteristics over a 4-year period using standardised assessments. The study will also explore potential metabolomic biomarkers and their relationship with clinical outcomes.

Detailed description

A prospective cohort to document the evolutionary trajectory over a 4-year period of patients with Dravet syndrome with a confirmed pathogenic or probably pathogenic variant in the SCN1A gene aged between 6 months and 21 years.

Pre-selection/eligibility stage Patients and their legal representatives will be contacted by an investigator. Inclusion and non-inclusion criteria will be assessed to confirm the participant's eligibility, allowing entry into the study and completion of the baseline assessment. Following a discussion of the objectives, risks and benefits of the study, the patient's non-objection to taking part in the research will be obtained, together with the patient's assent, if applicable.

Baseline assessment (Year 0)

An initial visit will be organized to collect demographic, historical and clinical data, and to carry out :

1. A detailed medical assessment (age, sex, history of seizures genetic diagnosis, co-morbidities, current treatments). 2. The Vineland-3 (parental module), analyzed by a psychologist 3. GMFM-66 for motor functions (by a physiotherapist). 4. CGI-S scale (clinician and carer) 5. An additional tube of blood taken during a blood test for metabolomics analysis (including serum GABA). 6. Bayley-IV (up to 8 years, depending on chronological or developmental age).

Annual visits (Years 1 to 4)

Annual assessments will be carried out to document clinical progress and will include:

1. A medical update (new diagnoses, types and frequency of seizures, treatments). 2. The same assessment tools as at the initial visit (Vineland-3, GMFM-66, CGI-S, Bayley-IV). 3. The CGI-I scale to measure changes since the previous visit. 4. An extra tube of blood taken during a blood test for metabolomics for metabolomic analysis. 5. The collection of data from medical examinations carried out as part of the treatment.

End of the study After four annual visits following the baseline assessment, the participant will complete the study. A final report will be drawn up to document the clinical and functional evolution of Dravet syndrome over a 4-year period

Primary outcome measures

• Score of scale Vineland-3 [Time frame: Up to 4 years]

Secondary outcome measures (5)

• Score of scale Gross Motor Function Measure-66 (GMFM-66) [Time frame: Up to 4 years]
• Score of scale Bayley-IV sub-domains [Time frame: Up to 4 years]
• Average Clinical Global Impressions (CGI) scale score at each age [Time frame: Up to 4 years]
• Score of improvement scale [Time frame: Up to 4 years]
• Dosage of serum GABA [Time frame: Up to 4 years]

Eligibility criteria

Inclusion criteria

• The patient or his/her legal representative must be able to give informed consent for participation in the study.
• The participant or legal representative are able (in the opinion of the investigator) to comply with the research protocol.
• Patient (male/female) between 6 months and 21 years of age inclusive at the time of consent.
• The patient has a confirmed pathogenic or probably pathogenic variant of the SCN1A gene demonstrated by a genetic test.
• The patient had normal development prior to the onset of the first seizure.
• The patient had an onset of epileptic seizures between the ages of 3 and 15 months inclusive.
• The patient is receiving at least one of the following anti-epileptic drugs prior to consent: brivaracetam, clobazam, cannabidiol, fenfluramine, levetiracetam, sodium valproate, stiripentol, topiramate

Exclusion criteria

• The patient has a copy number variation of the SCN1A gene affecting other genes, including a microdeletion of SCN1A.
• The patient has a mutation in the SCN1A gene on both alleles.
• The patient has a known or clinically suspected pathogenic mutation in a gene associated with epilepsy other than the SCN1A gene.
• The patient has a concomitant genetic mutation or clinical comorbidity deemed likely to disrupt the typical phenotype of Dravet syndrome.
• The patient has a known gain-of-function mutation, defined by functional studies, including p.Thr226Met.
• The patient has a history of neurodevelopmental abnormality prior to the onset of seizures, based on the medical record.
• The patient has been seizure free for a period of one year prior to informed consent.
• The patient has, at any time, taken antiepileptic drugs with a worsening effect for 6 consecutive weeks or more, including: carbamazepine, eslicarbazepine, lacosamide, lamotrigine, oxcarbazepine, phenytoin (chronic oral administration), tiagabine and vigabatrin.
• The patient has already received innovative therapies such as antisense ologonucleotides, gene therapy or cell therapy.
• The patient has a structural abnormality on brain imaging (MRI or CT scan) which the principal investigator considers to be an epileptogenic lesion.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model

Cohort

Study locations

France · 1 center

• Robert Debré Hospital — Paris

Identifiers

NCT: NCT07251673 · APHP241685 · 2024-A02640-47

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗